Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (331-340 of 352) with videos related to

Pageof 36
Sort By:
Journal of Crohn'S & Colitis|December 19, 2023
Outcomes and Endpoints of Postoperative Recurrence in Crohn's Disease: Systematic Review and Consensus ConferenceNassim Hammoudi, David Sachar, Geert D'Haens, et al.
Inflammatory Bowel Diseases|August 21, 2010
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meetingDaniel C Baumgart, Charles N Bernstein, Zaigham Abbas, et al.
Lancet (London, England)|July 20, 2025
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, Brian G Feagan, Anita Afzali, et al.
Lancet (London, England)|June 1, 2022
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trialsSilvio Danese, Séverine Vermeire, Wen Zhou, et al.
Journal of Crohn'S & Colitis|September 30, 2017
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA StudyGeert D'Haens, Séverine Vermeire, Harald Vogelsang, et al.
Journal of Clinical Medicine|July 29, 2023
Factors Associated with Response to Systemic Corticosteroids in Active Ulcerative Colitis: Results from a Prospective, Multicenter TrialAndreas Blesl, Andrea Borenich, Hans Peter Gröchenig, et al.
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|October 21, 2023
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBDSophie Vieujean, James O Lindsay, Ferdinando D'Amico, et al.
Inflammatory Bowel Diseases|July 18, 2023
Prediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition-A Prospective Multicenter StudyAndreas Blesl, Philipp Wurm, Silvio Waschina, et al.
The American Journal of Gastroenterology|November 4, 2010
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Geert R D'Haens, Remo Panaccione, Peter D R Higgins, et al.
Pageof 36

Showing results (331-340 of 352) with videos related to

Sort By:
Pageof 36
Journal of Crohn'S & Colitis|December 19, 2023
Outcomes and Endpoints of Postoperative Recurrence in Crohn's Disease: Systematic Review and Consensus ConferenceNassim Hammoudi, David Sachar, Geert D'Haens, et al.
Inflammatory Bowel Diseases|August 21, 2010
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meetingDaniel C Baumgart, Charles N Bernstein, Zaigham Abbas, et al.
Lancet (London, England)|July 20, 2025
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, Brian G Feagan, Anita Afzali, et al.
Lancet (London, England)|June 1, 2022
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trialsSilvio Danese, Séverine Vermeire, Wen Zhou, et al.
Journal of Crohn'S & Colitis|September 30, 2017
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA StudyGeert D'Haens, Séverine Vermeire, Harald Vogelsang, et al.
Journal of Clinical Medicine|July 29, 2023
Factors Associated with Response to Systemic Corticosteroids in Active Ulcerative Colitis: Results from a Prospective, Multicenter TrialAndreas Blesl, Andrea Borenich, Hans Peter Gröchenig, et al.
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|October 21, 2023
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBDSophie Vieujean, James O Lindsay, Ferdinando D'Amico, et al.
Inflammatory Bowel Diseases|July 18, 2023
Prediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition-A Prospective Multicenter StudyAndreas Blesl, Philipp Wurm, Silvio Waschina, et al.
The American Journal of Gastroenterology|November 4, 2010
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Geert R D'Haens, Remo Panaccione, Peter D R Higgins, et al.
Pageof 36